Precipio (PRPO) Q4 2025 earnings summary

Executive summary

• Achieved transition to positive cash flow in 2025, marking a strategic inflection point.

• Revenue grew 30% year-over-year to $24 million, driven by Pathology Services.

• Shifted from capital preservation to growth initiatives and long-term value creation.

Financial highlights

• Revenue reached $24 million in 2025, up 30% from 2024.

• Overall gross margin improved from 41% in 2024 to 45% in 2025.

• Pathology Services division drove most of the revenue and margin gains.

• Products Division saw Q4 gross margin spike to 90% due to concentrated production, with a baseline margin of 50%.

• All financial warrants exercised and Change Healthcare loan fully repaid, strengthening the balance sheet.

Outlook and guidance

• Focus for 2026 is on accelerating growth in the Products Division and expanding market share.

• Expect continued organic growth in Pathology Services and reinvestment of cash into Products.

• Revenue mix anticipated to shift toward a more balanced split between Pathology Services and Products over the next 3–5 years.